REGENXBIO Inc. RGNX
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2015 · data as of November 13, 2026
REGENXBIO Inc. (RGNX) is a healthcare company listed in the US with a market value of about $505M. In the twelve months to September 30, 2026 it had revenue of $154M and net income of -$175M, a net margin of -113.9%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 2% a year, a 5-year average ROIC of -51%.
About REGENXBIO
REGENXBIO is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2015. Revenue went from $6M in 2014 to $170M in 2025, growth of about 35.3% a year. It was profitable in 2 of the last 10 years in our data. Its share count rose by 20% over three years (dilution for shareholders). It spends 134% of revenue on research and development.
Score: 1.0 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $154M | $170M | $83M | $90M | $113M | $470M | $155M | $35M | $219M | $10M | $5M |
| Net income | -$175M | -$194M | -$227M | -$263M | -$280M | $128M | -$111M | -$95M | $100M | -$73M | -$63M |
| Free cash flow | -$155M | -$126M | -$176M | -$228M | -$238M | $135M | -$81M | -$119M | $91M | -$65M | -$57M |
| EPS (diluted) | $-3.21 | $-3.76 | $-4.59 | $-6.02 | $-6.50 | $2.91 | $-2.98 | $-2.58 | $2.73 | $-2.45 | $-2.38 |
| Net margin | -113.9% | -113.8% | -272.5% | -292.0% | -248.7% | 27.2% | -72.0% | -268.9% | 45.7% | -704.0% | -1372.1% |
| ROIC | — | -91.5% | -68.3% | -66.8% | -43.0% | 17.0% | -20.9% | -31.4% | 16.6% | -41.5% | -40.1% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 10 analysts is $21.40, 180% above the current price; targets range from $12.00 to $42.00; the consensus rating is “Strong buy”; expected EPS is $-3.58 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does REGENXBIO pay a dividend?
Not currently.
Is REGENXBIO a good stock to buy?
We do not give buy or sell advice. REGENXBIO scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.